Reported 26 days ago
A trio of biotech companies saw their shares rise significantly during their debut trading sessions after exceeding their initial public offering (IPO) targets. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma all sold more shares than planned, leading to notable price increases and marking a busy week for biotech IPOs—the most active since July 2021. The sector has generated $2.7 billion from IPOs this year, reflecting a nearly 60% increase from last year's figures, despite previous sluggish performances in the market.
Source: YAHOO